Theranostics 2019; 9(25):7792-7806. doi:10.7150/thno.35486 This issue
Opportunities and Challenges for Antibodies against Intracellular Antigens
1. Nanobody Research Center, Guangxi Medical University, Nanning, Guangxi, 530021, China
2. School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi, 530021, China
3. School of Stomatology, Guangxi Medical University, Nanning, Guangxi, 530021, China
*These authors contributed equally to this work.
Yang X, Xie S, Yang X, Cueva JC, Hou X, Tang Z, Yao H, Mo F, Yin S, Liu A, Lu X. Opportunities and Challenges for Antibodies against Intracellular Antigens. Theranostics 2019; 9(25):7792-7806. doi:10.7150/thno.35486. Available from https://www.thno.org/v09p7792.htm
Therapeutic antibodies are one most significant advances in immunotherapy, the development of antibodies against disease-associated MHC-peptide complexes led to the introduction of TCR-like antibodies. TCR-like antibodies combine the recognition of intracellular proteins with the therapeutic potency and versatility of monoclonal antibodies (mAb), offering an unparalleled opportunity to expand the repertoire of therapeutic antibodies available to treat diseases like cancer. This review details the current state of TCR-like antibodies and describes their production, mechanisms as well as their applications. In addition, it presents an insight on the challenges that they must overcome in order to become commercially and clinically validated.
Keywords: peptide, TCR-like antibody, MHC-peptide complex, CAR-T cell therapy